London, UK, 18 April 2023, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic collaboration agreement with Professor Chris Lord’s lab at The Institute of Cancer Research, London. The collaboration will use NeoPhore’s proprietary small molecule inhibitors of DNA mismatch repair (‘MMR’) to investigate single agent activity against tumours […]